Abcam, ab267718, Human IFN alpha/beta R2 (IFNAR2) Antibody Pair - BSA and Azide free

Size: 10 x 96Tests
Human IFN alpha/beta R2 (IFNAR2) Antibody Pair - BSA and Azide free is a kit containing recombinant capture and detector antibodies in a carrier-free formulation for the measurement of Human IFN alpha/beta R2 (IFNAR2).
Key facts
Reacts with:Human,
Assay type:ELISA set,
Range:46.875 - 3000 pg/mL,
Assay Platform:Reagents

Product details:
The Antibody Pair can be used to quantify Human IFN alpha/beta R2. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results.
For additional information on the performance of the antibody pair, see the equivalent SimpleStep ELISA® Kit (
ab264610
), which uses the same antibodies. However, due to differences in their formulation, this antibody pair cannot be used with the consumables provided with our SimpleStep ELISA Kits. Please note that the range provided for the pairs is only an estimation based on the performance of the related product using the same antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody pair in your assay.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
The pair can be used in variety of assays and platforms including but not limited to:
Sandwich ELISA
FRET/TR-FRET/HTRF
Meso Scale Discovery
Bead-based assays
AlphaLISA
/AlphaScreen
DELFIA
immunoassays
and Single Molecule Counting (SMC™) immunoassays
Multiplex
Our antibody pairs are supplied in a carrier-free format that is conjugation-ready:
Buffer free of BSA, sodium azide, and glycerol for higher conjugation efficiency.
Concentration of ~1 mg/ml as measured by the protein A280 method.
We can label antibodies for you: get in touch today to discuss how we can help accelerate your assay development with custom conjugation services.
Pairs are screened in biological samples, including plasma and serum, to ensure specificity in complex samples.
Please note:
The recommended antibody orientation is based on internal optimization in sandwich ELISA. Antibody orientation is assay dependent and needs to be optimized for each assay type.
The range provided for this antibody pair is based on initial sandwich ELISA validation data using recombinant protein. Performance and range of the antibody pair will depend on the specific characteristics of your assay, including standard protein selection.
We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibodies in other assays.
Antibody properties:
Capture antibody:
recombinant rabbit monoclonal (unconjugated) – 100 µg
Detector antibody:
recombinant rabbit monoclonal (unconjugated) - 100 µg
Concentration
: ~1 mg/ml
Storage buffer:
100% PBS
Liquid
Isotype:
Recombinant monoclonal antibodies offer several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free production
Meso Scale Discovery and MSD are registered trademarks of Meso Scale Diagnostics, LLC.
AlphaLISA, AlphaScreen, and DELFIA are registered trademarks of PerkinElmer, Inc.
Simoa is a registered trademark of Quanterix, Inc.
SMC is a registered trademark of Merck KGaA, Darmstadt, Germany.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IFNAR2 also known as Interferon Alpha/Beta Receptor 2 is a critical part of the immune system. It pairs with IFNAR1 to form the receptor complex binding type I interferons such as IFN-alpha and IFN-beta. The IFNAR2 protein itself weighs roughly 60 kDa. You can find it expressed on the surface of almost all cell types making it a versatile participant in cellular immune responses. Cellular assays such as IFN-alpha ELISA often use IFNAR2 to quantify type I interferon activity and researchers frequently study it to understand its role in immune regulation.
Biological function summary
IFNAR2 plays a role in mediating the effects of type I interferons. It forms part of a receptor complex with IFNAR1 to initiate signal transduction upon binding to its ligands leading to activation of the JAK-STAT signaling pathway. This pathway then induces the expression of interferon-stimulated genes (ISGs) that promote antiviral defense cell growth control and modulation of the immune response. Without the function of IFNAR2 within this complex cells would be unable to respond appropriately to viral infections.
Pathways
IFNAR2 is widely recognized in its involvement with the JAK-STAT pathway. Through this pathway IFNAR2 interacts closely with various proteins like JAK1 and STAT1 propagating the signal that leads to the transcription of numerous ISGs. Another vital pathway involving IFNAR2 is the induction of cytokines which influences the adaptive immune response. Its position within these pathways illustrates its functional importance in antiviral defense and immune system regulation.
IFNAR2 has associations with multiple sclerosis and systemic lupus erythematosus. In multiple sclerosis type I interferon pathways mediated by IFNAR2 can modulate immune responses implicated in the progression of this neurodegenerative disorder. Increased IFNAR2 activity might exacerbate lupus characterized by improper immune system regulation. IFN-alpha a cytokine closely linked to IFNAR2 plays a pivotal role in these conditions highlighting its importance in disease development and potential therapeutic targeting.